Javascript must be enabled to continue!
Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury
View through CrossRef
AbstractPregnancy loss and intrauterine growth restriction (IUGR) are serious pregnancy complications, and the triggers and mediators of placental and fetal damage are not completely understood. Using a mouse model of recurrent spontaneous miscarriages (DBA/2-mated CBA/J mice) that shares features with human recurrent miscarriage and fetal growth restriction, we identified tissue factor (TF) as an essential participating factor in placental and fetal injury. We have previously shown that C5a releases antiangiogenic molecule sFlt-1 in monocytes that causes defective placental development and fetal death in DBA/2-mated CBA/J mice. In this study, we found that TF not only activates the coagulation pathway, but it also mediates sFlt-1 release in monocytes causing defective placental development and fetal death. Blockade of TF with a monoclonal antibody inhibited sFlt-1 release, prevented the pathological activation of the coagulation pathway, restored placental blood flow, prevented placental oxidative stress, and rescued pregnancies. We also demonstrated that pravastatin, by down-regulating TF expression on monocytes and trophoblasts, prevented placental damage and protected pregnancies in DBA/2-mated CBA/J mice. These studies indicate that TF is an important mediator in fetal death and growth restriction and that statins may be a good treatment for women with recurrent miscarriages and IUGR.
American Society of Hematology
Title: Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury
Description:
AbstractPregnancy loss and intrauterine growth restriction (IUGR) are serious pregnancy complications, and the triggers and mediators of placental and fetal damage are not completely understood.
Using a mouse model of recurrent spontaneous miscarriages (DBA/2-mated CBA/J mice) that shares features with human recurrent miscarriage and fetal growth restriction, we identified tissue factor (TF) as an essential participating factor in placental and fetal injury.
We have previously shown that C5a releases antiangiogenic molecule sFlt-1 in monocytes that causes defective placental development and fetal death in DBA/2-mated CBA/J mice.
In this study, we found that TF not only activates the coagulation pathway, but it also mediates sFlt-1 release in monocytes causing defective placental development and fetal death.
Blockade of TF with a monoclonal antibody inhibited sFlt-1 release, prevented the pathological activation of the coagulation pathway, restored placental blood flow, prevented placental oxidative stress, and rescued pregnancies.
We also demonstrated that pravastatin, by down-regulating TF expression on monocytes and trophoblasts, prevented placental damage and protected pregnancies in DBA/2-mated CBA/J mice.
These studies indicate that TF is an important mediator in fetal death and growth restriction and that statins may be a good treatment for women with recurrent miscarriages and IUGR.
Related Results
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Poster 247: Muscle ERRγ Overexpression Mitigates the Muscle Atrophy after ACL injury
Objectives: Anterior cruciate ligament (ACL) reconstruction is the 6th most common orthopedic procedure performed in the United States (1,2). There is substantial evidence to sugge...
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Development and Clinical Significance of the Human Fetal Adrenal Gland as a Key Component of the Feto-Placental System: A Systematic Review
Development and Clinical Significance of the Human Fetal Adrenal Gland as a Key Component of the Feto-Placental System: A Systematic Review
Background: The human fetal adrenal gland is a unique endocrine organ with distinct morphology and functional dynamics, which is significantly different from the postnatal adrenal....
Combined Treatment with Low-Dose Pravastatin and Fish Oil in Post-Renal Transplantation Dislipidemia
Combined Treatment with Low-Dose Pravastatin and Fish Oil in Post-Renal Transplantation Dislipidemia
<i>Background:</i> The most common cause of post-transplant dyslipidemia is the use of corticosteroids and cyclosporin-A (CyA). The HMG-CoA reductase inhibitors have em...
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
GW24-e2259 Evaluation of atherosclerosis in low density lipoprotein receptor defect mice by ultrasound biomicroscopy
Objectives
Low density lipoprotein receptor defect mice model by transgenetic technology was used to detect atherosclerosis by Ultrasound Biology (UBM). And evalu...
Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
Familial combined hyperlipidemia (FCHL) is the most common genetic lipid disorder among young survivors of myocardial infarction. Elevations of plasma total and low-density lipopro...
Cell-specific Characterization of the Placental Methylome
Cell-specific Characterization of the Placental Methylome
Abstract
Background: DNA methylation (DNAm) profiling has emerged as a powerful tool for characterizing the placental methylome. However, previous studies have focused prim...


